Unknown

Dataset Information

0

Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.


ABSTRACT: The cytokine TNF is a well known drug target for several inflammatory diseases such as Crohn disease. Despite the great success of TNF blockers, therapy could be improved because of high costs and side effects. Selective inhibition of TNF receptor (TNFR) 1 signaling holds the potential to greatly reduce the pro-inflammatory activity of TNF, thereby preserving the advantageous immunomodulatory signals mediated by TNFR2. We generated a selective human TNFR1 inhibitor based on Nanobody (Nb) technology. Two anti-human TNFR1 Nbs were linked with an anti-albumin Nb to generate Nb Alb-70-96 named "TNF Receptor-One Silencer" (TROS). TROS selectively binds and inhibits TNF/TNFR1 and lymphotoxin-?/TNFR1 signaling with good affinity and IC50 values, both of which are in the nanomolar range. Surface plasmon resonance analysis reveals that TROS competes with TNF for binding to human TNFR1. In HEK293T cells, TROS strongly reduces TNF-induced gene expression, like IL8 and TNF, in a dose-dependent manner; and in ex vivo cultured colon biopsies of CD patients, TROS inhibits inflammation. Finally, in liver chimeric humanized mice, TROS antagonizes inflammation in a model of acute TNF-induced liver inflammation, reflected in reduced human IL8 expression in liver and reduced IL6 levels in serum. These results demonstrate the considerable potential of TROS and justify the evaluation of TROS in relevant disease animal models of both acute and chronic inflammation and eventually in patients.

SUBMITTER: Steeland S 

PROVIDER: S-EPMC4326813 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.

Steeland Sophie S   Puimège Leen L   Vandenbroucke Roosmarijn E RE   Van Hauwermeiren Filip F   Haustraete Jurgen J   Devoogdt Nick N   Hulpiau Paco P   Leroux-Roels Geert G   Laukens Debby D   Meuleman Philip P   De Vos Martine M   Libert Claude C  

The Journal of biological chemistry 20141223 7


The cytokine TNF is a well known drug target for several inflammatory diseases such as Crohn disease. Despite the great success of TNF blockers, therapy could be improved because of high costs and side effects. Selective inhibition of TNF receptor (TNFR) 1 signaling holds the potential to greatly reduce the pro-inflammatory activity of TNF, thereby preserving the advantageous immunomodulatory signals mediated by TNFR2. We generated a selective human TNFR1 inhibitor based on Nanobody (Nb) technol  ...[more]

Similar Datasets

| S-EPMC21562 | biostudies-literature
| 2161078 | ecrin-mdr-crc
| S-EPMC5534440 | biostudies-literature
| S-EPMC3517359 | biostudies-literature
| S-EPMC9623662 | biostudies-literature
| S-EPMC6308234 | biostudies-literature
| S-EPMC6282393 | biostudies-literature
| S-EPMC3136176 | biostudies-literature
| S-EPMC9325618 | biostudies-literature
| S-EPMC5517631 | biostudies-literature